Potentially Novel Approach for Treating Advanced Colorectal Cancer with KRAS Mutations.

Published Date: 15 Apr 2024

One-third of patients experience responses when using adagrasib plus cetuximab, with a median overall survival of 15 points 9 months.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Patients with resected head and neck cancers may benefit clinically from an investigational personalized vaccine.

2.

Guideline on management of early-stage non-small cell lung cancer released

3.

Pancreatic cancer patients who were prescribed lorazepam for anxiety had poorer survival rates.

4.

Medical debt in collections persists after cancer diagnosis

5.

Diet and Prostate Cancer; TTFields OK'd for NSCLC; Cancer Studies Retracted


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot